Monoclonal antibodies as analgesia of chronic low back pain: a systematic review and meta-analysis of efficacy and safety
Introduction. Monoclonal antibodies (mAb) emerged as a possible option in addressing the partial response to current treatment modalities in chronic low back pain (CLBP). Objective: to evaluate the efficacy and safety of mAb for CLBP. Materials and Methods. Randomized controlled trials on adul...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center of Neurology
2024-07-01
|
| Series: | Анналы клинической и экспериментальной неврологии |
| Subjects: | |
| Online Access: | https://annaly-nevrologii.com/journal/pathID/article/viewFile/1027/pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850197877506179072 |
|---|---|
| author | Nobel Budiputra Charista Lydia Budiputri Michelle Patricia Muljono |
| author_facet | Nobel Budiputra Charista Lydia Budiputri Michelle Patricia Muljono |
| author_sort | Nobel Budiputra |
| collection | DOAJ |
| description | Introduction. Monoclonal antibodies (mAb) emerged as a possible option in addressing the partial response to current treatment modalities in chronic low back pain (CLBP).
Objective: to evaluate the efficacy and safety of mAb for CLBP.
Materials and Methods. Randomized controlled trials on adult patients with CLBP who received mAb-therapy compared to those who did not as a control group. The result was the changes in Low Back Pain Intensity (LBPI) Numeric Rating Score and Roland–Morris Disability Questionnaire (RMDQ) indicating improved pain, disability, and the risk of adverse events. Meta-analysis, risk of bias, and confidence in the evidence for each analysis were assessed. We aimed at reviewing current treatment methods for degenerative lumbosacral spinal stenosis with an emphasis on surgical treatment methods.
Results. Six studies were included, with a total of 3851 participants. mAb significantly reduce LBPI and RMDQ score (weighted mean difference –1.48; 95% CI –2.63 to –0.33; p = 0.01). Tanezumab and fasinumab were significantly reduced both LBPI (weighted mean difference of –4.11; 95% CI –6.27 to –1.95; p = 0.0002 and weighted mean difference –0.24; 95% CI –0.47 to –0.02; p = 0.04 respectively) and RMDQ scores (weighted mean difference –3.72; 95% –5.48 to –1.97 and weighted mean difference –0.50; 95% –0.73 to –0.26 respectively, both p 0.0001). The mAb have significantly greater odds of any adverse events (OR 1.23; 95% 1.06 to 1.43; p = 0.007) but no greater odds regarding serious adverse events (OR 1.00; 95% 0.69 to 1.46; p = 0.98).
Conclusion. Depending on the types of drugs used, mAb had a favorable outcome and were relatively safe in reducing LBPI and RMDQ scores. |
| format | Article |
| id | doaj-art-2c605e5e7fbc4de79cca274417ed95de |
| institution | OA Journals |
| issn | 2075-5473 2409-2533 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Research Center of Neurology |
| record_format | Article |
| series | Анналы клинической и экспериментальной неврологии |
| spelling | doaj-art-2c605e5e7fbc4de79cca274417ed95de2025-08-20T02:13:01ZengResearch Center of NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-25332024-07-01182708310.17816/ACEN.1027689Monoclonal antibodies as analgesia of chronic low back pain: a systematic review and meta-analysis of efficacy and safetyNobel Budiputra0https://orcid.org/0009-0002-2197-064XCharista Lydia Budiputri1https://orcid.org/0000-0002-2129-842XMichelle Patricia Muljono2https://orcid.org/0000-0002-7764-4686Universitas Pelita HarapanUniversitas Pelita HarapanUniversitas Pelita HarapanIntroduction. Monoclonal antibodies (mAb) emerged as a possible option in addressing the partial response to current treatment modalities in chronic low back pain (CLBP). Objective: to evaluate the efficacy and safety of mAb for CLBP. Materials and Methods. Randomized controlled trials on adult patients with CLBP who received mAb-therapy compared to those who did not as a control group. The result was the changes in Low Back Pain Intensity (LBPI) Numeric Rating Score and Roland–Morris Disability Questionnaire (RMDQ) indicating improved pain, disability, and the risk of adverse events. Meta-analysis, risk of bias, and confidence in the evidence for each analysis were assessed. We aimed at reviewing current treatment methods for degenerative lumbosacral spinal stenosis with an emphasis on surgical treatment methods. Results. Six studies were included, with a total of 3851 participants. mAb significantly reduce LBPI and RMDQ score (weighted mean difference –1.48; 95% CI –2.63 to –0.33; p = 0.01). Tanezumab and fasinumab were significantly reduced both LBPI (weighted mean difference of –4.11; 95% CI –6.27 to –1.95; p = 0.0002 and weighted mean difference –0.24; 95% CI –0.47 to –0.02; p = 0.04 respectively) and RMDQ scores (weighted mean difference –3.72; 95% –5.48 to –1.97 and weighted mean difference –0.50; 95% –0.73 to –0.26 respectively, both p 0.0001). The mAb have significantly greater odds of any adverse events (OR 1.23; 95% 1.06 to 1.43; p = 0.007) but no greater odds regarding serious adverse events (OR 1.00; 95% 0.69 to 1.46; p = 0.98). Conclusion. Depending on the types of drugs used, mAb had a favorable outcome and were relatively safe in reducing LBPI and RMDQ scores.https://annaly-nevrologii.com/journal/pathID/article/viewFile/1027/pdfmonoclonal antibodytanezumabfasinumabfulranumabdenosumabchronic low back painlbpirmdq |
| spellingShingle | Nobel Budiputra Charista Lydia Budiputri Michelle Patricia Muljono Monoclonal antibodies as analgesia of chronic low back pain: a systematic review and meta-analysis of efficacy and safety Анналы клинической и экспериментальной неврологии monoclonal antibody tanezumab fasinumab fulranumab denosumab chronic low back pain lbpi rmdq |
| title | Monoclonal antibodies as analgesia of chronic low back pain: a systematic review and meta-analysis of efficacy and safety |
| title_full | Monoclonal antibodies as analgesia of chronic low back pain: a systematic review and meta-analysis of efficacy and safety |
| title_fullStr | Monoclonal antibodies as analgesia of chronic low back pain: a systematic review and meta-analysis of efficacy and safety |
| title_full_unstemmed | Monoclonal antibodies as analgesia of chronic low back pain: a systematic review and meta-analysis of efficacy and safety |
| title_short | Monoclonal antibodies as analgesia of chronic low back pain: a systematic review and meta-analysis of efficacy and safety |
| title_sort | monoclonal antibodies as analgesia of chronic low back pain a systematic review and meta analysis of efficacy and safety |
| topic | monoclonal antibody tanezumab fasinumab fulranumab denosumab chronic low back pain lbpi rmdq |
| url | https://annaly-nevrologii.com/journal/pathID/article/viewFile/1027/pdf |
| work_keys_str_mv | AT nobelbudiputra monoclonalantibodiesasanalgesiaofchroniclowbackpainasystematicreviewandmetaanalysisofefficacyandsafety AT charistalydiabudiputri monoclonalantibodiesasanalgesiaofchroniclowbackpainasystematicreviewandmetaanalysisofefficacyandsafety AT michellepatriciamuljono monoclonalantibodiesasanalgesiaofchroniclowbackpainasystematicreviewandmetaanalysisofefficacyandsafety |